Effect of aerosolized milrinone during drug-induced pulmonary hypertension in lambs

Pharmacological Research

Volumn 50, Issue 1, 2004, Pages 87-91

  Gelvez, Javier ^a   Fakioglu, Harun ^a   Olarte, Jose L ^a   Soliz, Amed ^a   Totapally, Balagangadhar R ^a   Torbati, Dan ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

Acute pulmonary hypertension; Lambs; Milrinone; Nebulization; Phosphodiesterase inhibitor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; MILRINONE; OXYGEN; THROMBOXANE A2;

AEROSOL; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG EFFECT; DRUG SCREENING; GAS ANALYSIS; GAS EXCHANGE; HEART OUTPUT; LAMB; LUNG ARTERY PRESSURE; MEAN ARTERIAL PRESSURE; NEBULIZATION; NEBULIZER; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC CIRCULATION; THERMODILUTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AEROSOLS; ANIMALS; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MILRINONE; PULMONARY GAS EXCHANGE; SHEEP; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 1842635493     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.12.005     Document Type: Article

References (28)

1. Everard ML, Le Souef PN. Aerosol therapy and delivery systems. In: Taussig LM, Landau LI, editors. Pediatric respiratory medicine. St. Louis: Mosby; 1999. p. 286-98.
2. Booke M., Bradford D.W., Hinder F., Harper D., Brauchle R.W., Traber L.D.et al. Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep. Crit. Care Med. 24:1996;1841-1848.
3. Max M., Kuhlen R., Dembinski R., Rossaint R. Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension. Intensive Care Med. 25:1999;1147-1154.
4. Meadow W., Rudinsky B., Bell A., Hipps R. Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Pediatr. Res. 44:1998;181-186.
5. Brilli R.J., Krafte-Jacobs B., Smith D.J., Passerini D., Moore L., Ballard E.T. Aerosolization of novel nitric oxide donors selectively reduces pulmonary hypertension. Crit. Care Med. 26:1998;1390-1396.
6. Ichinose F., Adrie C., Hurford W.E., Bloch K.D., Zapol W.M. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology. 88:1998;410-416.
7. Steinhorn R.H., Gordon J.B., Tod M.L. Site-specific effect of guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition in isolated lamb lungs. Crit. Care Med. 28:2000;490-495.
8. Nagamine J., Hill L., Pearl R.G. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit. Care Med. 28:2000;2420-2424.
9. Ichinose F., Erana-Garcia J., Hromi J., Raveh Y., Jones R., Krim L.et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit. Care Med. 29:2001;1000-1005.
10. Hashiba E., Hirota K., Hashimoto Y.H., Kudo T., Sato T., Matsuki A. Milrinone attenuates serotonine-induced pulmonary hypertension and bronchoconstriction in dogs. Anesth. Analg. 90:2000;790-794.
11. Kato R., Sato J., Nishino T. Milrinone decreases pulmonary arterial and venous resistance in the hypoxic dog. Br. J. Anaesth. 81:1998;920-924.
12. Deb B., Bradford K., Pearl R.G. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit. Care Med. 28:2000;795-799.
13. Chang A.C., Atz A.M., Wernovsky G., Burke R.P., Wessel D.L. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit. Care Med. 23:1995;1907-1914.
14. Sussmane J.B., Totapally B.R., Hultquist K., Torbati D., Wolfsdorf J. Effects of arteriovenous extracorporeal therapy on hemodynamic stability, ventilation, and oxygenation in normal lambs. Crit. Care Med. 29:2001;1972-1978.
15. Walsh-Sukys M.C., Tyson J.E., Wright L., Bauer C.R., Korones S.B., Steinson D.K.et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 105:2000;14-20.
16. Kinsella J.P., Truog W.E., Walsh W.F., Goldberg R.N., Bancalari E., Mayock D.E.et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J. Pediatr. 131(1 Pt 1):1977;55-56.
17. Mok Q., Yates R., Tasker R.C. Persistent pulmonary hypertension of the term neonate: a strategy for management. Eur. J. Pediatr. 158:1999;825-827.
18. Bartlett R.H., Roloff D., Custer J.R., Younger J.G., Hirschl R.B. Extracorporeal life support. The University of Michigan experience. J. Am. Med. Assoc. 283:2000;904-908.
19. Frostell C., Fratacci M.D., Wain J.C., Jones R., Zapol W.A. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 83:1991;2038-2047.
20. Rimar S., Gillis C.N. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation. 88:1993;2884-2887.
21. Clark R.H., Kueser T.J., Walker M.W., Southgate W.M., Huckaby J.L., Perez J.A.et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N. Eng. J. Med. 342:2000;469-474.
22. Christou H., Van Marter L.J., Wessel D., Allred E.N., Kane J.W., Thompson J.E.et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of newborn. Crit. Care Med. 28:2000;3722-3727.
23. Pepke-Zaba J., Higenbottam T.W., Dinh-Xuan A.T., Stone D., Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 338:1991;1173-1174.
24. Quin A.C., Vallance P. Inhaled nitric oxide - from pollutant to patent. Eur. J. Clin. Invest. 23:1993;445-447.
25. Nield T.A., Langenbacher D., Poulsen M.K., Platzker A.C. Neurodevelopment outcome at 3.5 years of age in children treated with extracorporeal life support: relation to primary diagnosis. J. Pediatr. 136:2000;338-344.
26. Newman S.P. Aerosol deposition considerations in inhalation therapy. Chest. 88:1985;152S-160S.
27. Phipps P.R., Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest. 97:1990;1327-1333.
28. Hess D., Fisher D., Williams P., Pooler S., Kacmarek R.M. Medication nebulizer performance: effects of different volume, nebulizer flow, and nebulizer brand. Chest. 110:1996;498-505.